The Association between Lymphocytic Thyroiditis and Papillary Thyroid Cancer Harboring Mutant BRAF : A Systematic Review and Meta-Analysis
Pooled result · Odds of PTC-BRAFResult — go to the resultOdds ratio 0.53 95% CI 0.48–0.58Authors' conclusion
The odds of PTC-BRAF are significantly lower in the presence of LT than without. PTC with LT, irrespective of BRAF status, was significantly associated with better prognostic factors.
Study context
- Population
- Adult patients with papillary thyroid cancer (PTC); observational studies published 2010 to June 2023 (PubMed, Embase, Web of Science)
- Participants
- 28,143 patients39 studies
- Comparison
- PTC with lymphocytic thyroiditis (LT) vs PTC without LT (BRAFV600E prevalence); BRAF-mutant vs wild-type PTC and PTC with vs without LT (adverse pathological features)
- Outcome
- Prevalence of PTC-BRAF with and without LT
Pooled result
Odds of PTC-BRAF
Odds ratio
0.53
95% CI 0.48–0.58
P < 0.00001
LTvs No LT
OR 0.53 (95% CI 0.48–0.58); P < 0.00001
As reported in the abstract
Further pooled results
| Outcome | Estimate | P value | |
|---|---|---|---|
| Adverse pathological features, PTC-BRAF vs wild-type PTC, irrespective of LT statusPTC-BRAFvs Wild-type PTC | OR, CNND 1.54 (95% CI 1.16–2.04) | ||
| Adverse pathological features, PTC-BRAF vs wild-type PTC, irrespective of LT statusPTC-BRAFvs Wild-type PTC | OR, PTC > 1 cm 1.14 (95% CI 0.82–1.58) | ||
| Adverse pathological features, PTC-BRAF vs wild-type PTC, irrespective of LT statusPTC-BRAFvs Wild-type PTC | OR, extra-thyroidal extension 1.66 (95% CI 1.40–1.97) | ||
| Adverse pathological features, PTC-BRAF vs wild-type PTC, irrespective of LT statusPTC-BRAFvs Wild-type PTC | OR, AJCC Stage 3-4 1.53 (95% CI 1.35–1.75) | ||
| Adverse pathological features, PTC-BRAF vs wild-type PTC, irrespective of LT statusPTC-BRAFvs Wild-type PTC | OR, multifocality 1.24 (95% CI 1.11–1.40) | ||
| Adverse pathological features, PTC with LT vs without LT, irrespective of BRAF statusLTvs No LT | OR, CNND 0.64 (95% CI 0.51–0.81) | ||
| Adverse pathological features, PTC with LT vs without LT, irrespective of BRAF statusLTvs No LT | OR, PTC > 1 cm 0.83 (95% CI 0.73–0.95) | ||
| Adverse pathological features, PTC with LT vs without LT, irrespective of BRAF statusLTvs No LT | OR, ETE 0.71 (95% CI 0.58–0.86) | ||
| Adverse pathological features, PTC with LT vs without LT, irrespective of BRAF statusLTvs No LT | OR, AJCC Stage 3-4 0.84 (95% CI 0.75–0.94) | ||
| PTC recurrencePTC-BRAFvs Wild-type PTC | OR 1.12 (95% CI 0.66–1.90) | P = 0.67 | |
| PTC recurrenceLTvs No LT | OR 0.60 (95% CI 0.28–1.30) | P = 0.20 | |
| 0.20.5125Ratio (log scale) |
PTC recurrence
- Similar results with recurrence expressed as HR in this limited data-set
Original publication
The Association between Lymphocytic Thyroiditis and Papillary Thyroid Cancer Harboring Mutant BRAF : A Systematic Review and Meta-Analysis. Thyroid. Published 18 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →